Thus, not surprisingly, KRAS and GNAS mutations in both high‐ and low‐risk IPMN patients are less frequently detected in liquid biopsy than in other analytes. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.